Free tool
FAERS Monitor: Zynlonta
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming BLA 761196 or its brand name (Zynlonta, Loncastuximab Tesirine-Lpyl). Reports on generic versions are filed under their own applications.
Reports
410
Serious
308
75% of reports
Hospitalization
110
Death reported
146
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- death69
- disease progression33
- rash32
- pleural effusion24
- fatigue22
- photosensitivity reaction21
- neutropenia18
- anaemia16
- thrombocytopenia15
- covid-1914
- oedema14
- off label use14
- pneumonia14
- diffuse large b-cell lymphoma13
- oedema peripheral12
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2017 | 1 |
| 2018 | 1 |
| 2019 | 1 |
| 2021 | 26 |
| 2022 | 84 |
| 2023 | 77 |
| 2024 | 62 |
| 2025 | 68 |
| 2026 | 90 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,749 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| diffuse large b-cell lymphomaSignal | 13 | 86.7 | 50.8 | 1,016 |
| photosensitivity reactionSignal | 21 | 65.3 | 43.1 | 1,266 |
| pleural effusionSignal | 24 | 20.2 | 13.7 | 421 |
| disease progressionSignal | 33 | 14.3 | 10.3 | 397 |
| oedemaSignal | 14 | 13.2 | 7.9 | 147 |
| thrombocytopeniaSignal | 15 | 6.9 | 4.2 | 70 |
| neutropeniaSignal | 18 | 6.8 | 4.3 | 84 |
| oedema peripheralSignal | 12 | 5.1 | 2.9 | 35 |
| anaemiaSignal | 16 | 4.3 | 2.7 | 38 |
| deathSignal | 69 | 4.1 | 3.3 | 166 |
| covid-19Signal | 14 | 4.1 | 2.4 | 30 |
| rashSignal | 32 | 3.8 | 2.7 | 64 |
| pneumoniaSignal | 14 | 2.2 | 1.3 | 8 |
| fatigue | 22 | 1.4 | 1.0 | 3 |
| off label use | 14 | 0.8 | 0.5 | 0 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.